Using Knowledge Graphs and SHACL to Validate Declaration Forms: an Experiment in the Social Security Domain to Assess SHACL's Applicability

peer reviewe

Just-in-time" generation of datasets by considering structured representations of given consent for GDPR compliance

peer reviewe

One year of DALIDA Data Literacy Workshops for Adults: A Report

peer reviewe

On the Move to Meaningful Internet Systems: OTM 2015 Workshops: Confederated International Workshops: OTM Academy, OTM Industry Case Studies Program, EI2N, FBM, INBAST, ISDE, META4eS, and MSC 2015, Rhodes, Greece, October 26-30, 2015. Proceedings

International audienceThis volume constitutes the refereed proceedings of the following 8 International Workshops: OTM Academy; OTM Industry Case Studies Program; Enterprise Integration, Interoperability, and Networking, EI2N; International Workshop on Fact Based Modeling 2015, FBM; Industrial and Business Applications of Semantic Web Technologies, INBAST; Information Systems, om Distributed Environment, ISDE; Methods, Evaluation, Tools and Applications for the Creation and Consumption of Structured Data for the e-Society, META4eS; and Mobile and Social Computing for collaborative interactions, MSC 2015. These workshops were held as associated events at OTM 2015, the federated conferences "On The Move Towards Meaningful Internet Systems and Ubiquitous Computing", in Rhodes, Greece, in October 2015.The 55 full papers presented together with 3 short papers and 2 popsters were carefully reviewed and selected from a total of 100 submissions. The workshops share the distributed aspects of modern computing systems, they experience the application pull created by the Internet and by the so-called Semantic Web, in particular developments of Big Data, increased importance of security issues, and the globalization of mobile-based technologies

Screening of repeated dose toxicity data in safety evaluation reports of cosmetic ingredients issued by the Scientific Committee on Consumer Safety between 2009 and 2019

peer reviewe

Development of the TOXIN Knowledge Graph for Assisting Animal-free Risk Assessment of Cosmetic Ingredients

editorial reviewe

Development of an easy-to-use, semantic technology-based knowledge base containing toxicological information of cosmetic ingredients to assist animal-free risk assessment

peer reviewe

Tracking the Near Eastern origins and European dispersal of the western house mouse

Abstract: The house mouse (Mus musculus) represents the extreme of globalization of invasive mammals. However, the timing and basis of its origin and early phases of dispersal remain poorly documented. To track its synanthropisation and subsequent invasive spread during the develoment of complex human societies, we analyzed 829 Mus specimens from 43 archaeological contexts in Southwestern Asia and Southeastern Europe, between 40,000 and 3,000 cal. BP, combining geometric morphometrics numerical taxonomy, ancient mitochondrial DNA and direct radiocarbon dating. We found that large late hunter-gatherer sedentary settlements in the Levant, c. 14,500 cal. BP, promoted the commensal behaviour of the house mouse, which probably led the commensal pathway to cat domestication. House mouse invasive spread was then fostered through the emergence of agriculture throughout the Near East 12,000 years ago. Stowaway transport of house mice to Cyprus can be inferred as early as 10,800 years ago. However, the house mouse invasion of Europe did not happen until the development of proto urbanism and exchange networks — 6,500 years ago in Eastern Europe and 4000 years ago in Southern Europe — which in turn may have driven the first human mediated dispersal of cats in Europe

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Abstract Background Though the Expanded Disability Status Scale (EDSS) is commonly used to assess disability level in relapsing-remitting multiple sclerosis (RRMS), the criteria defining disability progression are used for patients with a wide range of baseline levels of disability in relatively short-term trials. As a result, not all EDSS changes carry the same weight in terms of future disability, and treatment benefits such as decreased risk of reaching particular disability milestones may not be reliably captured. The objectives of this analysis are to assess the probability of confirmed disability worsening to specific EDSS milestones (i.e., EDSS scores ≥3.0, ≥4.0, or ≥6.0) at 288 weeks in the Tysabri Observational Program (TOP) and to examine the impact of relapses occurring during natalizumab therapy in TOP patients who had received natalizumab for ≥24 months. Methods TOP is an ongoing, open-label, observational, prospective study of patients with RRMS in clinical practice. Enrolled patients were naive to natalizumab at treatment initiation or had received ≤3 doses at the time of enrollment. Intravenous natalizumab (300 mg) infusions were given every 4 weeks, and the EDSS was assessed at baseline and every 24 weeks during treatment. Results Of the 4161 patients enrolled in TOP with follow-up of at least 24 months, 3253 patients with available baseline EDSS scores had continued natalizumab treatment and 908 had discontinued (5.4% due to a reported lack of efficacy and 16.4% for other reasons) at the 24-month time point. Those who discontinued due to lack of efficacy had higher baseline EDSS scores (median 4.5 vs. 3.5), higher on-treatment relapse rates (0.82 vs. 0.23), and higher cumulative probabilities of EDSS worsening (16% vs. 9%) at 24 months than those completing therapy. Among 24-month completers, after approximately 5.5 years of natalizumab treatment, the cumulative probabilities of confirmed EDSS worsening by 1.0 and 2.0 points were 18.5% and 7.9%, respectively (24-week confirmation), and 13.5% and 5.3%, respectively (48-week confirmation). The risks of 24- and 48-week confirmed EDSS worsening were significantly higher in patients with on-treatment relapses than in those without relapses. An analysis of time to specific EDSS milestones showed that the probabilities of 48-week confirmed transition from EDSS scores of 0.0–2.0 to ≥3.0, 2.0–3.0 to ≥4.0, and 4.0–5.0 to ≥6.0 at week 288 in TOP were 11.1%, 11.8%, and 9.5%, respectively, with lower probabilities observed among patients without on-treatment relapses (8.1%, 8.4%, and 5.7%, respectively). Conclusions In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0–9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of ≥1.0 or ≥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS score 4.0–5.0 to ≥6.0 in the absence of relapses suggest that relapses remain a significant driver of disability worsening and that on-treatment relapses in natalizumab-treated patients are of prognostic importance